See more : Gold Peak Technology Group Limited (0040.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Goodbody Health Limited (GDBYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Goodbody Health Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Exxaro Resources Limited (EXX.JO) Income Statement Analysis – Financial Results
- MediNet Group Limited (8161.HK) Income Statement Analysis – Financial Results
- Algonquin Power & Utilities Corp. (AQN.TO) Income Statement Analysis – Financial Results
- PT Cerestar Indonesia Tbk (TRGU.JK) Income Statement Analysis – Financial Results
- Shanghai Yaohua Pilkington Glass Group Co., Ltd. (600819.SS) Income Statement Analysis – Financial Results
Goodbody Health Limited (GDBYF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.goodbodyhealth.com
About Goodbody Health Limited
Goodbody Health Inc., a wellness company, provides health and wellness range of products and services in the United Kingdom. The company also operates as a vertically integrated cannabinoid (CBD) company that operates in the United Kingdom and the European Union. It has interests in COVID and blood testing clinics, CBD extraction, wholesale bulk isolate and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal cannabis research programs. The company was formerly known as Sativa Wellness Group Inc. and changed its name to Goodbody Health Inc. in January 2022. The company is headquartered in Vancouver, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.06M | 1.99M | 1.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.13M | 870.53K | 695.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.93M | 1.12M | 754.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.36% | 56.35% | 52.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.27M | 4.74M | 3.53M | 175.40K | 14.06K | 40.11K | 46.03K | 46.19K | 40.30K | 42.42K |
| Selling & Marketing | 4.22M | 539.98K | 471.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 5.28M | 4.00M | 175.40K | 14.06K | 40.11K | 46.03K | 46.19K | 40.30K | 42.42K |
| Other Expenses | 446.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.93M | 5.77M | 4.31M | 175.40K | 14.06K | 42.82K | 148.62K | 52.45K | 40.30K | 42.42K |
| Cost & Expenses | 17.06M | 6.64M | 5.00M | 175.40K | 14.06K | 42.82K | 148.62K | 52.45K | 40.30K | 42.42K |
| Interest Income | 0.00 | 63.54K | 0.00 | 0.00 | 0.00 | 2.48K | 0.00 | 2.61K | 3.82K | 964.53 |
| Interest Expense | 0.00 | 27.02K | 0.00 | 1.27K | 77.53 | 0.00 | 0.00 | 0.00 | 40.12 | 56.55 |
| Depreciation & Amortization | 1.04M | 471.39K | 259.54K | 493.77 | 161.48K | 22.82K | 30.69K | 0.00 | 3.82K | 1.02K |
| EBITDA | -13.74K | -4.12M | -3.29M | -175.40K | 147.35K | -42.82K | -118.04K | -52.45K | -36.48K | -41.45K |
| EBITDA Ratio | -0.08% | -200.32% | -211.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 321.62K | -4.47M | -3.32M | -175.90K | -14.13K | -42.82K | -148.73K | -52.45K | -40.30K | -42.47K |
| Operating Income Ratio | 1.89% | -223.96% | -229.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | -195.69K | -477.72K | -625.84K | -161.33K | 2.42K | -30.58K | 2.57K | 3.78K | 964.53 |
| Income Before Tax | -2.25M | -4.79M | -3.80M | -348.81K | -175.46K | -40.40K | -179.20K | -49.87K | -36.52K | -41.51K |
| Income Before Tax Ratio | -13.17% | -240.04% | -261.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 67.63K | -128.17K | 244.56K | 780.68 | -77.53 | -22.82K | -112.82 | 0.00 | 0.00 | 0.00 |
| Net Income | -2.31M | -4.66M | -3.80M | -348.81K | -175.46K | -40.40K | -179.20K | -49.87K | -36.52K | -41.51K |
| Net Income Ratio | -13.57% | -233.61% | -261.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.29 | -0.48 | -0.17 | -0.18 | -0.08 | -0.35 | -0.16 | -0.12 | -0.52 |
| EPS Diluted | -0.07 | -0.29 | -0.48 | -0.17 | -0.18 | -0.08 | -0.35 | -0.16 | -0.12 | -0.52 |
| Weighted Avg Shares Out | 34.62M | 16.25M | 7.96M | 2.01M | 975.18K | 525.55K | 509.81K | 315.80K | 315.80K | 79.38K |
| Weighted Avg Shares Out (Dil) | 34.62M | 16.25M | 7.96M | 2.01M | 975.18K | 525.55K | 509.81K | 315.80K | 315.80K | 79.38K |
Goodbody Health in distribution tie-up with blood collection specialist Tasso
Goodbody Health has signed a distribution contract with Tasso Inc, a specialist in equipment for collecting clinical-grade blood samples without needles. Through the collaboration, Goodbody's clinics can now undertake diagnostic tests requiring more blood than is delivered through the finger...
Goodbody Health's Howells cheers ‘new era' as cancer testing increasingly catches disease earlier
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) chief executive Marc Howells has cheered a new era in which blood testing is increasingly detecting the presence of cancer cells early, allowing earlier diagnosis that can help save lives. The UK-listed health, wellness and...
Goodbody Health revenues rise 52% as Covid testing continues
Goodbody Health Inc (AQSE:GDBY, CSE:GDBY, OTCQB:GDBYF). said revenue rose 52% in the first half of 2022, though the pace slowed towards the end of the period with an easing in demand for Covid PCR tests.
Goodbody Health launching cancer and heart disease genetic tests
Goodbody Health Inc (AQSE:GDBY, CSE:GDBY, OTCQB:GDBYF) said it is launching new genetic tests to help people understand their risk of cancer and heart disease. It will do so in conjunction with Everything Genetic, the testing services specialist, to provide four...
Goodbody Health clinics now registered with Care Quality Commission
Goodbody Health Inc (AQSE:GDBY, CSE:GDBY, OTCQB:GDBYF) said its network of clinics is now registered with the Care Quality Commission for its health testing services. Having applied last year, the company said it had successfully passed registration criteria to provide services...
Goodbody Health to re-domicle in Guernsey and de-list from CSX
Goodbody Health said it is to de-list from the Canadian Stock Exchange (CSE), re-domicile to Guernsey and appoint Peterhouse as its corporate adviser “This re-domiciliation is intended to better align Goodbody's corporate structure with its current and future business activities,”...
Goodbody Health launches health 'MOT' to test for diabetes and cholesterol risk
Goodbody Health Inc (AQSE:GBDY, CSE:GBDY, OTC:SCNNF) said it is launching a health ‘MOT' test to be offered at its UK high street stores and via pharmacies, where customers will get results of diabetes and cholesterol tests “in minutes”. Priced at...
Goodbody Health cheers record profit as strong Covid test numbers continued into Q1
Goodbody Health Inc (AQSE:GBDY, CSE:GBDY, OTC:SCNNF) cheered its highest quarterly profit to date, driven by a 276% jump in year-on-year revenues generated through its patient testing operations. The company said it experienced a strong continuation of bookings for Covid PCR...
Goodbody Health breaks into the black after diversification outside CBD into testing clinics
Goodbody Health Inc (AQSE:GBDY, CSE:GBDY, OTC:SCNNF) broke into the black in 2021 as it diversified into testing clinics, with revenue and gross profit 755% and 695% higher. The wellness products and services group announced an underlying profit (adjusted EBITDA) of...
Source: https://incomestatements.info
Category: Stock Reports